Trial Profile
A phase II study of Erlotinib and Bevacizumab combination therapy for previously treated III B / IV Stage non-squamous non-small cell lung cancer: IMSLC-001
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 22 Sep 2013 New trial record